Methyl Aminolevulinate Topical Dosage
This dosage information may not include all the information needed to use Methyl Aminolevulinate Topical safely and effectively. See additional information for Methyl Aminolevulinate Topical.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Keratosis
Non-hyperkeratotic, nonpigmented actinic keratoses of the face and scalp in immunocompetent patients: Apply directly on lesion(s), up to a total of 1 gram (half tube) per each treatment session. Two sessions one week apart should be administered. Cream application should be followed by photoactivation with Aktilite CL 128 lamp red light illumination.
Prior to cream application, a small dermal curette should be used to remove scales and crusts and to roughen the surface of the lesion(s). An approximately 1 mm-thick layer of cream should be applied with a spatula to each lesion and the surrounding 5 mm of normal skin. The application area should then be covered with an occlusive, nonabsorbent dressing for 3 hours (2.5 to 4 hours). Multiple lesions may be treated during the same session, up to an area of 80 X 180 mm (the area of illumination).
Following removal of the occlusive dressing, clean the area with saline and gauze before beginning Aktilite red light treatment. The light dose to be used is 37 J/cm2, and the lamp should be placed 50 to 80 mm (2 to 3.2 inches) from the skin. The required illumination time (7 to 10 minutes) is calculated automatically. Both the patient and operator should wear appropriate eye protection during illumination and avoid staring into the beam. The illumination stops automatically.
If Aktilite red light treatment is interrupted or stopped for any reason, it may be restarted. If the patient cannot have the red light treatment during the prescribed period after application, the cream should be rinsed off and the patient should protect the exposed area from sunlight and prolonged or intense light for at least 48 hours.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Use of methyl aminolevulinate cream without subsequent red light illumination is not recommended.
Methyl aminolevulinate cream is not indicated for ophthalmic, oral, or intravaginal use.
Methyl aminolevulinate cream has demonstrated a high rate of contact sensitization. Physicians should take caution to avoid inadvertent skin contact, and wear Nitrile (not vinyl or latex) gloves for protection when applying and removing the cream.
Following application of the cream, patients should avoid exposure of the photosensitive treatment sites to sunlight or bright indoor light (e.g., examination or operating room lamps; tanning beds; lights at close proximity) until they undergo photoactivation with Aktilite red light treatment. Exposure to light may result in a stinging and/or burning sensation and may cause erythema and/or edema of the lesions. Appropriate head covering such as a wide-brimmed hat and adequate clothing should be worn to protect treated areas from light and extreme cold when going outside. Sunscreens will not protect against photosensitivity reactions caused by visible light.
Before operating the Aktilite CL128 lamp, personnel should refer to the Operators Manual for specific warnings, cautions, and instructions. During the red light illumination period, the patient, operator, and other persons present should wear protective goggles that sufficiently screen out the appropriate spectrum of red light.
After illumination of methyl aminolevulinate cream, the treated area should be kept covered and away from light for at least 48 hours.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Data not available
Transient pain, burning, or stinging may occur at the target lesion sites during the period of light exposure.
Redness, swelling, burning, and stinging are normal following therapy. However, the doctor should be notified if these symptoms increase in severity and persist for more than 3 weeks.
Lesion response should be evaluated 3 months after completion of therapy.